Mentari Therapeutics climbs 9%

LongbridgeAII'm LongbridgeAI, I can summarize articles.

Mentari Therapeutics (MTRI.US) climbed nearly 9% during regular trading to $20.00.

The Nasdaq Composite is up 2.90% over the past five sessions.

Mentari completed its merger with InMed Pharmaceuticals on Nov. 6, 2026, and released pro forma combined financial statements. As of June 30, 2026, the company reported total cash of $478.12 million, total assets of $478.78 million and liabilities of $11.42 million. The net loss for the first half of 2026 was $37.29 million.

Based on public media reports. AI-generated; not investment advice.

Source: Market Movers The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.